Blinatumomab meets endpoint early in ALL
This article was originally published in Pharmaceutical Approvals Monthly
The success of Micromet's blinatumomab meeting the primary endpoint in a Phase II study in acute lymphocytic leukemia is being viewed by investors as "striking" results. The study tested the BiTE antibody in 21 patients with minimal residual disease - that is, patients who retain a detectable level of ALL cells in the bone marrow after chemotherapy. Results reported in Berlin at the European Hematology Association June 8 showed that 13 of 16 patients evaluated so far, 81 percent, yielded a response. The study had only to show at least 22 percent response to achieve the primary efficacy endpoint. Patients in all subgroups responded to treatment with blinatumomab. Micromet also is testing the biologic in non-Hodgkin's lymphoma
You may also be interested in...
California proposes limiting short-form Prop 65 warnings to products with 5 inches or less of labeling space, while prohibiting their use in online and catalog warnings. The number of products with the warnings, used even on vacuum cleaners, luggage and guitars, has made tracking them impossible.
While endocrine-disrupting evidence was inconclusive, the Scientific Committee on Consumer Safety recommends more conservative limits on use of homosalate, octocrylene and benzophenone-3 in cosmetic products compared with current requirements under the European Cosmetics Product Regulation.
The risk of inadvertently growing SARS-CoV-2 virus in cell and gene therapies and possibly infecting patients and workers should be assessed and mitigated, the agency advises.